Home

Search

Pathway AI

Account ⋅ Sign Out

Table of contents

Vulvovaginal candidiasis

Key sources
The following summarized guidelines for the evaluation and management of vulvovaginal candidiasis are prepared by our editorial team based on guidelines from the Center for Disease Control (CDC 2021), the American College of Obstetricians and Gynecologists (ACOG 2020), the International Union Against Sexually Transmitted Infections (IUSTI/WHO 2018), the Infectious Diseases Society of America (IDSA 2016), the Society of Obstetricians and Gynaecologists of Canada (SOGC 2015), and the AIDSinfo Society (AIDSInfo 2009).
1
2
3
4
5
6

Guidelines

1.Screening and diagnosis

Diagnosis: as per IUSTI 2018 guidelines, obtain microscopy as the current best test for the diagnosis of VVC.
B
Create free account

2.Medical management

Antifungal therapy, agents
Recognize that OTC intravaginal agents for VVC include:
Situation
Guidance
Clotrimazole
1% cream 5 g intravaginally daily for 7-14 days
2% cream 5 g intravaginally daily for 3 days
Miconazole
2% cream 5 g intravaginally daily for 7 days
4% cream 5 g intravaginally daily for 3 days
100 mg vaginal suppository one suppository daily for 7 days
200 mg vaginal suppository one suppository for 3 days
1,200 mg vaginal suppository one suppository for 1 day
Tioconazole
6.5% ointment 5 g intravaginally in a single application
E
Recognize that prescription drugs for VVC include:
Situation
Guidance
Butoconazole
2% cream (single-dose bioadhesive product) 5 g intravaginally in a single application
Terconazole
0.4% cream 5 g intravaginally daily for 7 days
0.8% cream 5 g intravaginally daily for 3 days
80 mg vaginal suppository one suppository daily for 3 days
Fluconazole
150 mg PO in a single dose
E

More topics in this section

  • Antifungal therapy (uncomplicated disease)

  • Antifungal therapy (severe disease)

  • Management of recurrence

3.Specific circumstances

Pregnant patients: administer topical azole preparations for the treatment of VVC in pregnant patients.
B

More topics in this section

  • Patients with C. glabrata infection

  • Patients with HIV